Browsing Category
Medicine
Pfizer: Pfizer Presents First Data from Planned Interim Analysis of Pivotal Phase 2 MagnetisMM-3…
Pfizer Inc. (NYSE: PFE) today announced new data from a planned interim analysis of the Phase 2 MagnetisMM-3 registration-enabling trial of elranatamab in people with relapsed/refractory multiple myeloma (RRMM) whose disease is refractory!-->…
Pfizer: Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S.
Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Michigan, facility, enabling U.S.-based production in support of its!-->…
Pfizer: Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for…
Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and!-->…
People lifting weights to look good risk reverse anorexia
Research from The University of Queensland has found people lifting weights for aesthetic reasons run the risk of developing muscle dysmorphia.
Also called ‘reverse anorexia’ or ‘bigorexia’, muscle dysmorphia is characterised by…
Pfizer: Pfizer Launches ‘An Accord for a Healthier World’ to Improve Health Equity for 1.2 Billion…
Pfizer Inc. (NYSE: PFE) today launched ‘An Accord for a Healthier World.’ This groundbreaking initiative aims to provide all of Pfizer’s patented, high-quality medicines and vaccines available in the U.S. or the European Union on a!-->…
Pfizer: Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the…
Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Pfizer’s investigational combination therapy for the treatment of non-alcoholic steatohepatitis (NASH) with liver!-->…
Pfizer: Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and…
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced topline safety, immunogenicity and vaccine efficacy data from a Phase 2/3 trial evaluating a third 3-µg dose of the Pfizer-BioNTech COVID-19 Vaccine in children 6!-->…
Pfizer: Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod’s Potentially Best-in-Class…
Pfizer Inc. (NYSE: PFE) today announced detailed results from two pivotal studies that make up the ELEVATE UC Phase 3 registrational program evaluating etrasimod, a once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor!-->…
Dapagliflozin met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death…
High-level results from the DELIVER Phase III trial showed AstraZeneca’s dapagliflozin reached a statistically significant and clinically meaningful reduction in the primary composite endpoint of cardiovascular (CV) death or worsening heart…
Racial gap in doctor visits disappeared in 2020 as telemedicine adopted
PHILADELPHIA— Historically, there has been racial inequity when it comes to primary care appointments, which are vital for managing and preventing chronic disease. But as COVID-19 struck the United States in 2020 and telemedicine…